Chiome Bioscience (TSE:4583) Loans Receivable: 円0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
52 GF Score
Price 円75.00
GF Value 円83.81
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Chiome Bioscience Loans Receivable?

Chiome Bioscience TSE:4583 +2.74% 52 Loans Receivable is 円0.0 Mil as of Dec. 2025. GuruFocus rates TSE:4583 with a GF Score™ of 52/100 and a GF Value™ of 円83.81 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Chiome Bioscience's Loans Receivable for the quarter that ended in Dec. 2025 was 円0.0 Mil.

Chiome Bioscience Loans Receivable Related Terms

Chiome Bioscience Loans Receivable Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Loans Receivable Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chiome Bioscience Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4583
52GF Score
Chiome Bioscience Inc TSE:4583
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of 円0.0 Mil mean?
Chiome Bioscience (TSE:4583) has a Loans Receivable of 円0.0 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's Loans Receivable too high?
Chiome Bioscience's current Loans Receivable is 円0.0 Mil. Overall, Chiome Bioscience has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Loans Receivable compare to VRTX and REGN?
Chiome Bioscience's Loans Receivable of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Loans Receivable is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Undervalued. The stock's GF Value™ is 円83.81, compared to a current price of 円75.00 — trading 10.5% below its estimated fair value. The current Loans Receivable is 円0.0 Mil. Chiome Bioscience's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Loans Receivable is 円0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円75.00 is trading 10.5% below its estimated GF Value™ of 円83.81. GuruFocus considers Chiome Bioscience to be Modestly Undervalued.

Key valuation signals for TSE:4583:

  • Loans Receivable: 円0.0 Mil
  • GF Value™: 円83.81 vs. price of 円75.00 (10.5% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
52GF Score

Get the complete analysis for TSE:4583

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円75.00
Price
円83.81
GF Value